The safety and preliminary efficacy of AZD0156 were evaluated alone or in combination with other anti-cancer treatments in patients with advanced cancer. AZD0156 enhanced the tumour growth inhibitory effects of radiation treatment and potentiates the effects of PARP inhibitors like Olaparib as well as showed synergistic effects with irinotecan in this study. This evidence concerns the gene PARP1 and neoplasm.